• EV-Transferred ACLY Reprograms Macrophages in HCC

  2026-09-23

  The study identifies extracellular vesicle (EV)-transferred ATP-citrate lyase (ACLY) as a metabolic signal that helps convert monocytes into immunosuppressive tumor-associated macrophages in hepatocellular carcinoma. Its engineered vesicle experiments support a causal role for ACLY and suggest that selectively targeting this pathway may improve checkpoint immunotherapy, while leaving important questions about clinical translation and broader tumor relevance.

• Epinephrine Bitartrate: Adrenergic Research Guide

  2026-09-23

  Epinephrine Bitartrate is a non-selective adrenergic receptor agonist for controlled α- and β-receptor activation in cell, cardiovascular, and translational studies. Product specifications and a canine pharmacokinetic study support distinct research-use benchmarks, but canine intranasal exposure does not establish human dose equivalence.

• CSBTA Pharmacokinetics in MASH Mice

  2026-09-22

  The reference study integrates pharmacokinetics, tissue distribution, cellular transport, and metabolic-enzyme analysis to explain how MASH alters exposure to Corydalis saxicola Bunting total alkaloids. Its findings indicate that disease state and repeated dosing can increase systemic and hepatic exposure, providing a mechanistic basis for more rational dose design in MASLD/MASH research.

• α-Bungarotoxin for Nicotinic Receptor Blockade

  2026-09-22

  Use α-Bungarotoxin as a high-affinity α7 nAChR antagonist to separate receptor-dependent cholinergic effects from downstream toxicity, inflammation, and cell-death signals. This practical workflow connects classical neuroscience experiments with the placental necroptosis model reported in recent research.

• Pyridostigmine, Placental Necroptosis, and α7 nAChR

  2026-09-21

  This study identifies placental necroptosis as a modifiable feature of preeclampsia-like disease in rats and links pyridostigmine activity to α7 nicotinic acetylcholine receptor signaling. Its combined human tissue, RUPP rat, antagonist, inhibitor, and trophoblast-cell experiments provide a mechanistic framework for studying non-neuronal cholinergic regulation of placental ischemic injury.

• BMS 599626 dihydrochloride Workflow Guide

  2026-09-21

  Build reproducible EGFR/HER2 phosphorylation, proliferation, and senescence-adjacent assays with BMS 599626 dihydrochloride. This workflow distinguishes direct receptor inhibition from downstream cell-state effects and translates machine-learning-guided senolytic discovery into practical experimental design.

• Separating Growth Inhibition from Cell Death In Vitro

  2026-09-20

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these measurements capture different relationships between proliferative arrest and drug-induced cell death. The framework provides a practical basis for designing time-aware cancer drug assays and avoiding overinterpretation of a single viability endpoint.

• Q-VD(OMe)-OPh in Apoptosis Assays

  2026-09-19

  Q-VD(OMe)-OPh provides a practical way to separate caspase-dependent apoptosis from ferroptosis, autophagy, and other stress responses in combination-treatment studies. This workflow-centered guide shows how to use it in resistant cancer models, differentiation experiments, and neuroprotection research while avoiding common interpretation and formulation errors.

• Carrier-Platin and the Intracellular ROS Storm

  2026-09-18

  Liu et al. describe carrier-platin, a platinum nanotherapeutic that confines ultrasmall platinum-based nanoparticles within a poly(amino acids) carrier to generate a rapid intracellular reactive oxygen species burst. The study links this ROS surge to non-apoptotic, non-ferroptotic cancer-cell death that is independent of DNA damage, with activity reported across cancer models, including multidrug-resistant settings.

• Topotecan HCl: Reliable Cancer Cell Assays

  2026-09-18

  Learn how Topotecan HCl, SKU B2296, can support reproducible viability, proliferation, and cytotoxicity studies through mechanism-aware dosing, solvent control, and improved interpretation of growth inhibition versus cell death. This scenario-based guide connects product specifications with practical cancer research workflows.

• Tiamulin: From Ribosome Binding to Assay Design

  2026-09-17

  Tiamulin (Thiamutilin) is more than a veterinary pleuromutilin antibiotic: its ribosomal binding geometry, resistance biology, pharmacodynamic targets, and anti-inflammatory activity directly shape experimental design. This guide connects molecular mechanism to microbiology, animal studies, and translational assay decisions.

• Rotavirus Suppression of Nrf2 Redox Defense

  2026-09-17

  The reference study shows that rotavirus infection produces a biphasic Nrf2 response: an early, oxidative-stress-associated increase followed by pronounced Nrf2 depletion and loss of antioxidant gene expression. Its mechanistic contribution is the finding that late Nrf2 loss is not restored by blocking canonical Keap1/Cul3-Rbx1 turnover but is associated with proteasome activity and K48-linked ubiquitination, providing a framework for interpreting viral disruption of host redox defense.

• Carrier-Platin and Rapid ROS Cancer Cell Death

  2026-09-16

  Liu et al. developed carrier-platin, a platinum nanotherapeutic that confines ultrasmall platinum-based nanoparticles within a poly(amino acids) carrier to generate a rapid intracellular reactive oxygen species burst. The study links this ROS storm to cancer-cell death that is distinct from conventional platinum-induced apoptosis and shows activity in multidrug-resistant models with limited systemic toxicity in preclinical testing.

• DNA Frameworks Improve Enzymatic Oligonucleotide Synthesis

  2026-09-16

  Li and colleagues introduce a tetrahedral DNA nanostructure interface that organizes primers for more accessible and efficient enzymatic oligonucleotide synthesis. The framework improved substrate accessibility, reduced deletion errors in patterned sequences, and supported synthesis of a 60-nucleotide information-storage fragment with a reported stepwise yield of 96.82%.

• Pyridostigmine Targets Placental Necroptosis in PE

  2026-09-15

  A 2026 study links enhanced non-neuronal cholinergic signaling with suppression of placental necroptosis in preeclampsia-like disease. Using RUPP rats, trophoblast hypoxia experiments, α-bungarotoxin blockade, and necrostatin-1 comparison, the authors identify α7 nicotinic acetylcholine receptor signaling as a mechanistic contributor rather than a merely associated pathway.

8063 records 1/538 page Next 12345 下5页 Last page